Browse the site

Start with a goal 53 things people take supplements for — sleep, stress, joints, focus.
Home Get the app

Evidence map Updated

Peripheral Neuropathy

Peripheral neuropathy is damage to the nerves that carry signals between your body and your brain. It causes burning, tingling, weakness, or numbness — most often in the hands and feet — and is most commonly driven by diabetes, chemotherapy, or vitamin deficiencies.

9 ingredients · 4 outcomes · 9 trials

Evidence map: Peripheral Neuropathy

Peripheral neuropathy is damage to the nerves that carry signals between your body and your brain. It causes burning, tingling, weakness, or numbness — most often in the hands and feet — and is most commonly driven by diabetes, chemotherapy, or vitamin deficiencies.

Across 9 ingredients and 4 outcomes, this map shows 19 studied pairs covering 9 distinct clinical trials.

Where cells are blank, the (ingredient, outcome) pair has not been studied — 17 such gaps remain on this map.

Coverage matrix

Where the evidence is — and where it isn't

Milder neuropathy severity Milder neuropathy severity Milder nerve symptoms after chemotherapy Milder nerve symptoms after chemotherapy Fewer nerve pain symptoms Fewer nerve pain symptoms Less neuropathy disability Less neuropathy disability Acetyl L-Carnitine Agmatine Alpha Lipoic Acid Benfotiamine Cyanocobalamin Methylcobalamin Palmitoylethanolamide Vitamin B1 Vitamin B12 1 Acetyl L-Carnitine × Milder neuropathy severity — 1 studies, n=540, GRADE: low 1 Acetyl L-Carnitine × Milder nerve symptoms after chemotherapy — 1 studies, n=409, GRADE: moderate Acetyl L-Carnitine × Fewer nerve pain symptoms — Not studied Acetyl L-Carnitine × Less neuropathy disability — Not studied 1 Agmatine × Milder neuropathy severity — 1 studies, n=12, GRADE: very_low Agmatine × Milder nerve symptoms after chemotherapy — Not studied 1 Agmatine × Fewer nerve pain symptoms — 1 studies, n=12, GRADE: very_low Agmatine × Less neuropathy disability — Not studied 2 Alpha Lipoic Acid × Milder neuropathy severity — 2 studies, n=455, GRADE: moderate Alpha Lipoic Acid × Milder nerve symptoms after chemotherapy — Not studied 1 Alpha Lipoic Acid × Fewer nerve pain symptoms — 1 studies, n=128, GRADE: very_low 1 Alpha Lipoic Acid × Less neuropathy disability — 1 studies, n=460, GRADE: moderate 1 Benfotiamine × Milder neuropathy severity — 1 studies, n=57, GRADE: low Benfotiamine × Milder nerve symptoms after chemotherapy — Not studied Benfotiamine × Fewer nerve pain symptoms — Not studied 1 Benfotiamine × Less neuropathy disability — 1 studies, n=57, GRADE: low 1 Cyanocobalamin × Milder neuropathy severity — 1 studies, n=665, GRADE: moderate Cyanocobalamin × Milder nerve symptoms after chemotherapy — Not studied 1 Cyanocobalamin × Fewer nerve pain symptoms — 1 studies, n=90, GRADE: low Cyanocobalamin × Less neuropathy disability — Not studied 1 Methylcobalamin × Milder neuropathy severity — 1 studies, n=665, GRADE: moderate Methylcobalamin × Milder nerve symptoms after chemotherapy — Not studied 1 Methylcobalamin × Fewer nerve pain symptoms — 1 studies, n=90, GRADE: low Methylcobalamin × Less neuropathy disability — Not studied 1 Palmitoylethanolamide × Milder neuropathy severity — 1 studies, n=66, GRADE: low Palmitoylethanolamide × Milder nerve symptoms after chemotherapy — Not studied 2 Palmitoylethanolamide × Fewer nerve pain symptoms — 2 studies, n=80, GRADE: moderate Palmitoylethanolamide × Less neuropathy disability — Not studied 1 Vitamin B1 × Milder neuropathy severity — 1 studies, n=57, GRADE: low Vitamin B1 × Milder nerve symptoms after chemotherapy — Not studied Vitamin B1 × Fewer nerve pain symptoms — Not studied 1 Vitamin B1 × Less neuropathy disability — 1 studies, n=57, GRADE: low 1 Vitamin B12 × Milder neuropathy severity — 1 studies, n=665, GRADE: moderate Vitamin B12 × Milder nerve symptoms after chemotherapy — Not studied 1 Vitamin B12 × Fewer nerve pain symptoms — 1 studies, n=90, GRADE: low Vitamin B12 × Less neuropathy disability — Not studied
Each cell = one (ingredient, outcome) pair. Number = trial count; shading = GRADE certainty (darker = stronger evidence). Outlined cells have not been studied.
  • High certainty
  • Moderate
  • Low
  • Very low
  • Not studied

Risk-of-bias

Cochrane RoB2 across the contributing trials

Randomization Deviations Missing data Measurement Reporting Overall Ziegler D 2011 + Ziegler D 2011 — Randomization: low + Ziegler D 2011 — Deviations: low + Ziegler D 2011 — Missing data: low + Ziegler D 2011 — Measurement: low Ziegler D 2011 — Reporting: no information Ziegler D 2011 — Overall: no information Garcia-Alcala H 2015 ? Garcia-Alcala H 2015 — Randomization: some concerns − Garcia-Alcala H 2015 — Deviations: high + Garcia-Alcala H 2015 — Missing data: low − Garcia-Alcala H 2015 — Measurement: high + Garcia-Alcala H 2015 — Reporting: low − Garcia-Alcala H 2015 — Overall: high Hershman D 2018 Hershman D 2018 — Randomization: no information + Hershman D 2018 — Deviations: low ? Hershman D 2018 — Missing data: some concerns + Hershman D 2018 — Measurement: low Hershman D 2018 — Reporting: no information Hershman D 2018 — Overall: no information Passiatore M 2020 ? Passiatore M 2020 — Randomization: some concerns − Passiatore M 2020 — Deviations: high + Passiatore M 2020 — Missing data: low − Passiatore M 2020 — Measurement: high Passiatore M 2020 — Reporting: no information − Passiatore M 2020 — Overall: high Didangelos T 2021 + Didangelos T 2021 — Randomization: low + Didangelos T 2021 — Deviations: low + Didangelos T 2021 — Missing data: low + Didangelos T 2021 — Measurement: low + Didangelos T 2021 — Reporting: low + Didangelos T 2021 — Overall: low Pickering E 2022 + Pickering E 2022 — Randomization: low + Pickering E 2022 — Deviations: low + Pickering E 2022 — Missing data: low + Pickering E 2022 — Measurement: low + Pickering E 2022 — Reporting: low + Pickering E 2022 — Overall: low Lang-Illievich K 2022 + Lang-Illievich K 2022 — Randomization: low + Lang-Illievich K 2022 — Deviations: low + Lang-Illievich K 2022 — Missing data: low + Lang-Illievich K 2022 — Measurement: low + Lang-Illievich K 2022 — Reporting: low + Lang-Illievich K 2022 — Overall: low Davis M 2024 ? Davis M 2024 — Randomization: some concerns + Davis M 2024 — Deviations: low ? Davis M 2024 — Missing data: some concerns + Davis M 2024 — Measurement: low Davis M 2024 — Reporting: no information ? Davis M 2024 — Overall: some concerns Ziegler D 2026 + Ziegler D 2026 — Randomization: low + Ziegler D 2026 — Deviations: low ? Ziegler D 2026 — Missing data: some concerns + Ziegler D 2026 — Measurement: low + Ziegler D 2026 — Reporting: low ? Ziegler D 2026 — Overall: some concerns
Cochrane RoB2 ratings across 9 randomized trials. Each row is one trial; columns are the five RoB2 domains plus the overall judgement.
  • Low risk
  • Some concerns
  • High risk
  • Not reported

Effect-size scatter

Effect direction, sample size, and certainty in one view

-2 -1 -0.5 0 +0.5 +1 +2 Cohen's d (positive = beneficial) 10 30 100 300 1000 Total participants (log scale) Alpha Lipoic Acid × Neuropathy Symptom Severity — d=0.15, n=455, 2 studies, GRADE moderate, Unclear if it helps Cyanocobalamin × Neuropathy Symptom Severity — d=0.35, n=665, 1 studies, GRADE moderate, Probably helps a little Cyanocobalamin × Neuropathic Pain Symptoms — d=0.43, n=90, 1 studies, GRADE low, May help Methylcobalamin × Neuropathy Symptom Severity — d=0.35, n=665, 1 studies, GRADE moderate, Probably helps a little Methylcobalamin × Neuropathic Pain Symptoms — d=0.43, n=90, 1 studies, GRADE low, May help Palmitoylethanolamide × Neuropathy Symptom Severity — d=1.68, n=66, 1 studies, GRADE low, May help a lot Palmitoylethanolamide × Neuropathic Pain Symptoms — d=1.01, n=80, 2 studies, GRADE moderate, Probably helps a lot Vitamin B12 × Neuropathy Symptom Severity — d=0.35, n=665, 1 studies, GRADE moderate, Probably helps a little Vitamin B12 × Neuropathic Pain Symptoms — d=0.43, n=90, 1 studies, GRADE low, May help
9 studied pairs. Each dot = one (ingredient, outcome) combination. Distance left/right of zero shows effect direction; vertical axis shows trial sample size (log-scaled); fill style and color = GRADE certainty (solid = higher certainty, ring = lower).
  • High
  • Moderate
  • Low
  • Very low

Methodology

Coverage cells, GRADE bands, and Cohen's d values come from suplmnt's evidence-scoring pipeline; risk-of-bias ratings map paper-level extraction signals onto the five Cochrane RoB2 domains per the Cochrane Handbook (2024 edition, §8). Empty cells reflect a true absence of trials, not a missing extraction. Generated 2026-10-24 from 9 contributing trials.

Related

Explore the evidence behind Peripheral Neuropathy

Want personalized recommendations?

Show me what works for me